These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 16297793

  • 1. Improvement of renal dysfunction by conversion from calcineurin inhibitors to sirolimus after heart transplantation.
    Hunt J, Lerman M, Magee MJ, Dewey TM, Herbert M, Mack MJ.
    J Heart Lung Transplant; 2005 Nov; 24(11):1863-7. PubMed ID: 16297793
    [Abstract] [Full Text] [Related]

  • 2. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
    Sayin B, Karakayali H, Colak T, Sevmis S, Pehlivan S, Demirhan B, Haberal M.
    Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
    [Abstract] [Full Text] [Related]

  • 3. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [Abstract] [Full Text] [Related]

  • 4. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK, Rohr MS, Hartmann EL, Adams PL, Stratta RJ.
    Clin Transplant; 2004 Nov; 18 Suppl 12():61-6. PubMed ID: 15217410
    [Abstract] [Full Text] [Related]

  • 5. Sirolimus as an alternative to anticalcineurin therapy in heart transplantation: experience of a single center.
    Fernandez-Valls M, Gonzalez-Vilchez F, de Prada JA, Ruano J, Ruisanchez C, Martin-Duran R.
    Transplant Proc; 2005 Nov; 37(9):4021-3. PubMed ID: 16386615
    [Abstract] [Full Text] [Related]

  • 6. Sirolimus-based immunosuppression after cardiac transplantation: predictors of recovery from calcineurin inhibitor-induced renal dysfunction.
    Gustafsson F, Ross HJ, Delgado MS, Bernabeo G, Delgado DH.
    J Heart Lung Transplant; 2007 Oct; 26(10):998-1003. PubMed ID: 17919619
    [Abstract] [Full Text] [Related]

  • 7. Sirolimus experience in heart transplantation.
    Aranda-Dios A, Lage E, Sobrino JM, Mogollón MV, Guisado A, Cabezón S, Hinojosa R, Hernández A, Ordóñez A.
    Transplant Proc; 2006 Oct; 38(8):2547-9. PubMed ID: 17097997
    [Abstract] [Full Text] [Related]

  • 8. Recovery of renal function in heart transplantation patients after conversion from a calcineurin inhibitor-based therapy to sirolimus.
    Ayub-Ferreira SM, Avila MS, Feitosa FS, Souza GE, Mangini S, Marcondes-Braga FG, Issa VS, Bacal F, Chizzola PR, Cruz FD, Bocchi EA.
    Transplant Proc; 2010 Mar; 42(2):542-4. PubMed ID: 20304188
    [Abstract] [Full Text] [Related]

  • 9. Preservation of renal function after heart transplantation: initial single-center experience with sirolimus.
    De Meester JM, Van Vlem B, Walravens M, Vanderheyden M, Verstreken S, Goethals M, Kerre N, Wellens F.
    Transplant Proc; 2005 May; 37(4):1835-8. PubMed ID: 15919481
    [Abstract] [Full Text] [Related]

  • 10. Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients.
    Nair S, Eason J, Loss G.
    Liver Transpl; 2003 Feb; 9(2):126-9. PubMed ID: 12548505
    [Abstract] [Full Text] [Related]

  • 11. Calcineurin inhibitor substitution with sirolimus vs. reduced-dose calcineurin inhibitor plus sirolimus is associated with improved renal dysfunction in heart transplant patients.
    Potter BJ, Giannetti N, Edwardes MD, Cecere R, Cantarovich M.
    Clin Transplant; 2007 Feb; 21(3):305-8. PubMed ID: 17488377
    [Abstract] [Full Text] [Related]

  • 12. Conversion to sirolimus in renal transplant recipients: a single-center experience.
    Yelken B, Caliskan Y, Ozkan O, Gorgulu N, Yazici H, Turkmen A, Sever MS.
    Artif Organs; 2010 Aug; 34(8):E230-7. PubMed ID: 20618227
    [Abstract] [Full Text] [Related]

  • 13. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A, Töz H, Sen S, Alkan FT, Nart A, Aykas A, Doğan M, Postaci H, Sahin T, Simşek C.
    Transplant Proc; 2009 Mar; 41(2):756-63. PubMed ID: 19328973
    [Abstract] [Full Text] [Related]

  • 14. Long-term results after conversion from calcineurin inhibitors to sirolimus in renal transplant patients.
    Martinez-Mier G, Avila-Pardo SF, Mendez-Lopez MT, Budar-Fernandez LF.
    Clin Transplant; 2010 Mar; 24(4):467-73. PubMed ID: 19744089
    [Abstract] [Full Text] [Related]

  • 15. An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency.
    Peddi VR, Jensik S, Pescovitz M, Pirsch J, Adler SH, Thistlethwaite JR, Vincenti F, Cohen DJ.
    Clin Transplant; 2005 Feb; 19(1):130-6. PubMed ID: 15659146
    [Abstract] [Full Text] [Related]

  • 16. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency.
    Yang YJ, Chen DZ, Li LX, Kou JT, Lang R, Jin ZK, Han DD, He Q.
    Transplant Proc; 2008 Jun; 40(5):1541-4. PubMed ID: 18589147
    [Abstract] [Full Text] [Related]

  • 17. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity.
    Kushwaha SS, Khalpey Z, Frantz RP, Rodeheffer RJ, Clavell AL, Daly RC, McGregor CG, Edwards BS.
    J Heart Lung Transplant; 2005 Dec; 24(12):2129-36. PubMed ID: 16364861
    [Abstract] [Full Text] [Related]

  • 18. Sirolimus monotherapy effectiveness in liver transplant recipients with renal dysfunction due to calcineurin inhibitors.
    Di Benedetto F, Di Sandro S, De Ruvo N, Spaggiari M, Montalti R, Ballarin R, Cappelli G, Gerunda GE.
    J Clin Gastroenterol; 2009 Mar; 43(3):280-6. PubMed ID: 19057397
    [Abstract] [Full Text] [Related]

  • 19. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
    DuBay D, Smith RJ, Qiu KG, Levy GA, Lilly L, Therapondos G.
    Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
    [Abstract] [Full Text] [Related]

  • 20. Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplantation patients.
    Balfour IC, Srun SW, Wood EG, Belsha CW, Marshall DL, Ferdman BR.
    J Heart Lung Transplant; 2006 May; 25(5):518-22. PubMed ID: 16678029
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.